Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy

被引:15
作者
Randall, Michael P. [1 ]
Spinner, Michael A. [1 ]
机构
[1] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA
关键词
Hodgkin lymphoma; relapsed/refractory; brentuximab vedotin; checkpoint inhibitor; PD-1; inhibitor; nivolumab; pembrolizumab; autologous hematopoietic cell transplantation; STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMORADIOTHERAPY; TUMOR-ASSOCIATED MACROPHAGES; REED-STERNBERG CELLS; BRENTUXIMAB VEDOTIN; PHASE-II; SALVAGE THERAPY; SINGLE-CENTER; OPEN-LABEL; FOLLOW-UP;
D O I
10.3390/cancers15184509
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Classic Hodgkin lymphoma (cHL) has a high cure rate with chemotherapy, but 10-30% of patients experience relapse or refractory (R/R) disease, depending on stage and risk factors. Treatment for R/R cHL differs between young, fit patients who are eligible for high-dose chemotherapy and autologous stem cell transplants and older adults who are not eligible for intensive therapies. Over the past decade, management of R/R cHL has evolved significantly following the approval of three highly active novel agents: brentuximab vedotin, nivolumab, and pembrolizumab, leading to improved cure rates and overall survival. In this review, we discuss our approach to the treatment of first relapse, maintenance therapy after transplant, relapse after transplant, and management of older adults and frail patients. Finally, we highlight emerging immunotherapies in clinical trials that hold great promise for the future.Abstract Most patients with classic Hodgkin lymphoma (cHL) are cured with combination chemotherapy, but approximately 10-20% will relapse, and another 5-10% will have primary refractory disease. The treatment landscape of relapsed/refractory (R/R) cHL has evolved significantly over the past decade following the approval of brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, and the PD-1 inhibitors nivolumab and pembrolizumab. These agents have significantly expanded options for salvage therapy prior to autologous hematopoietic cell transplantation (AHCT), post-transplant maintenance, and treatment of relapse after AHCT, which have led to improved survival in the modern era. In this review, we highlight our approach to the management of R/R cHL in 2023 with a focus on choosing first salvage therapy, post-transplant maintenance, and treatment of relapse after AHCT. We also discuss the management of older adults and transplant-ineligible patients, who require a separate approach. Finally, we review novel immunotherapy approaches in clinical trials, including combinations of PD-1 inhibitors with other immune-activating agents as well as novel antibody-drug conjugates, bispecific antibodies, and cellular immunotherapies. Ongoing studies assessing biomarkers of response to immunotherapy and dynamic biomarkers such as circulating tumor DNA may further inform treatment decisions and enable a more personalized approach in the future.
引用
收藏
页数:23
相关论文
共 50 条
[41]   FDG-PET in Relapsed/Refractory Hodgkin Lymphoma: a practical approach. [J].
Tomarchio, Valeria ;
Rigacci, Luigi .
CHEMOTHERAPY, 2024, 69 (01) :1-10
[42]   Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma [J].
Ge, Shiliang ;
Lepic, Kylie ;
Bhindi, Ravi ;
Berg, Tobias ;
Khalaf, Dina ;
Leber, Brian ;
Radford, Michael ;
Walker, Irwin ;
Davies, Gwynivere ;
Garcia-Horton, Alejandro .
CURRENT ONCOLOGY, 2025, 32 (02)
[43]   Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition? [J].
Othman, Tamer ;
Herrera, Alex ;
Mei, Matthew .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2021, 16 (01) :1-7
[44]   Refractory Hodgkin Lymphoma [J].
von Tresckow, Bastian ;
Engert, Andreas .
CURRENT OPINION IN ONCOLOGY, 2013, 25 (05) :463-469
[45]   Addressing an Unmet Need in Relapsed or Refractory Hodgkin Lymphoma comment [J].
Sheikh, Semira ;
Kuruvilla, John .
JCO ONCOLOGY PRACTICE, 2021, 17 (02) :74-+
[46]   Combination of Brentuximab Vedotin and Pembrolizumab as Salvage Treatment Before Autologous Stem Cell Transplantation and Maintenance in Patients with Relapsed/Refractory Hodgkin Lymphoma [J].
Massa, Hanne ;
Massaro, Fulvio ;
Maerevoet, Marie .
BIOMEDICINES, 2025, 13 (02)
[47]   Sequencing novel agents in the treatment of classical Hodgkin lymphoma [J].
Ferhanoglu, Burhan ;
Ozbalak, Murat .
EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (12) :991-1015
[48]   Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis [J].
Plattel, Wouter J. ;
Bergamasco, Aurore ;
Trinchese, Fabrizio ;
Gavini, Francois ;
Bent-Ennakhil, Nawal ;
Zomas, Athanasios ;
Castillon, Genaro ;
Arredondo-Bisono, Teigna ;
Cristarella, Tiffany ;
Moride, Yola ;
von Tresckow, Bastian .
LEUKEMIA & LYMPHOMA, 2021, 62 (14) :3320-3332
[49]   Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma [J].
Casadei, Beatrice ;
Argnani, Lisa ;
Morigi, Alice ;
Lolli, Ginevra ;
Broccoli, Alessandro ;
Pellegrini, Cinzia ;
Nanni, Laura ;
Stefoni, Vittorio ;
Coppola, Paolo E. ;
Carella, Matteo ;
Cavo, Michele ;
Zinzani, Pier Luigi .
CANCER MEDICINE, 2020, 9 (21) :7830-7836
[50]   Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents [J].
Faisal, Muhammad Salman ;
Hanel, Walter ;
Voorhees, Timothy ;
Li, Rui ;
Huang, Ying ;
Khan, Abdullah ;
Bond, David ;
Sawalha, Yazeed ;
Reneau, John ;
Alinari, Lapo ;
Baiocchi, Robert ;
Christian, Beth ;
Maddocks, Kami ;
Efebera, Yvonne ;
Penza, Sam ;
Saad, Ayman ;
Brammer, Jonathan ;
DeLima, Marcos ;
Jaglowski, Samantha ;
Epperla, Narendranath .
CANCER MEDICINE, 2023, 12 (07) :8228-8237